DRI Healthcare Trust (TSE:DHT.UN) Price Target Raised to C$25.50

DRI Healthcare Trust (TSE:DHT.UN) had its price objective increased by National Bank Financial from C$23.50 to C$25.50 in a research report released on Tuesday morning,BayStreet reports. They currently have an outperform rating on the stock.

DHT.UN has been the subject of a number of other reports. Canaccord Genuity Group upped their price target on shares of DRI Healthcare Trust from C$22.25 to C$23.00 and gave the stock a “buy” rating in a research note on Tuesday, June 30th. Raymond James Financial upped their target price on DRI Healthcare Trust from C$22.50 to C$23.50 and gave the stock a “strong-buy” rating in a research report on Monday, June 29th. Finally, Stifel Nicolaus lifted their target price on DRI Healthcare Trust from C$25.00 to C$26.00 and gave the stock a “buy” rating in a report on Tuesday, August 11th. One analyst has rated the stock with a Strong Buy rating and four have assigned a Buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of C$25.60.

DRI Healthcare Trust Stock Up 1.3%

Shares of DHT.UN opened at C$18.37 on Tuesday. The firm has a 50-day moving average price of C$17.62 and a 200 day moving average price of C$17.38. The firm has a market capitalization of C$1.01 billion, a PE ratio of -22.96 and a beta of 0.37. DRI Healthcare Trust has a 52-week low of C$14.10 and a 52-week high of C$19.75.

DRI Healthcare Trust Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, July 20th. Stockholders of record on Monday, July 20th were given a dividend of $0.11 per share. This represents a $0.44 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date was Tuesday, June 30th. DRI Healthcare Trust’s dividend payout ratio is -52.50%.

About DRI Healthcare Trust

DRI Healthcare is a pioneer in global pharmaceutical royalty monetization. Since our founding in 1989, we have deployed more than $3 billion, acquiring more than 75 royalties on 50-plus drugs, including Eylea, Keytruda, Lumvoa, Orserdu, Remicade, Spinraza, Stelara, Vonjo and Zytiga. DRI Healthcare’s units are listed and trade on the TSX in Canadian dollars under the symbol ‘DHT.UN’ and in U.S. dollars under the symbol ‘DHT.U’. To learn more, visit drihealthcare.com or follow us on LinkedIn.